Details

Autor(en) / Beteiligte

• Pohl, Gudrun
• Krajnik, Gerhard
• Malayeri, Reza
• Müller, Rolf-Michael
• Klepetko, Walter
• Eckersberger, Franz
• Schäfer-Prokop, Cornelia
• Pokrajac, Boris
• Schmeikal, Susanne
• Maier, Alfred
• Ambrosch, Gerhard
• Woltsche, Michael
• Minar, Wilma
• Pirker, Robert

Titel

Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer

Ist Teil von

• Lung cancer (Amsterdam, Netherlands), 2006-10, Vol.54 (1), p.63-67

Ort / Verlag

Shannon: Elsevier Ireland Ltd

Erscheinungsjahr

2006

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Induction chemotherapy may improve clinical outcome of locally advanced non-small cell lung cancer (NSCLC). To further pursue this, the Austrian Association for the Study of Lung Cancer (AASLC) performed a multi-center phase II trial with TIP induction chemotherapy (Taxol ®175 mg/m 2 over 3 h on day 1, ifosfamide 1000 mg/m 2 daily on days 1–3, cisplatin 60 mg/m 2 on day 1, and prophylactic filgrastim 5 μg/kg daily on days 4–13). Treatment cycles were repeated every 3 weeks for 3 cycles. Then patients were re-staged and selected for local treatment. Forty-seven patients (33 male, 14 female; median age 58 years, range 36–78; 22 cIIIA, 25 cIIIB; 26 adenocarcinomas, 14 squamous cell carcinomas, 4 large cell carcinomas, 3 undifferentiated carcinomas) were included in this trial. Forty-five patients were evaluable for response and toxicity. An overall response rate of 43% (complete remission 4.5% and partial remission 38%) was achieved. Stable disease and progressive disease were seen in 38 and 15% of the patients, respectively. Down-staging occurred in 36% of the patients. The toxicities of the chemotherapy were mild and, in particular, no severe hematotoxicity was observed. Surgery was performed in 24 (51%) patients and resulted in complete tumor resection in 19 patients. Twenty-four patients received thoracic radiotherapy, 10 patients after surgery. Median survival was 10.3 months for the total population, 13.5 months for patients with cIIIA and 10 months for patients with clinical cIIIB. Survival was longer for patients with down-staging as compared to those without (median not reached versus 10 months, p = 0.005) and for patients with complete tumor resection as compared to the remaining patients (27 months versus 10 months, p = 0.05). In conclusion, the TIP regimen shows activity and good tolerance as induction chemotherapy in patients with locally advanced NSCLC.